Staidson(Beijing) Biopharmaceuticals Co.,Ltd. Posted 125.8 Million Yuan Net Loss in First Three Quarters of 2021

Staidson(Beijing) Biopharmaceuticals Co.,Ltd. (舒泰神(北京)生物制药股份有限公司) (300204.SZ) reported a net loss of 125.8 million yuan in the first three quarters of 2021, widening 28.1% year-on-year.

Meanwhile, the company posted 426.3 million yuan in revenue, up 43.9% year-on-year.

At the end of the reporting period, it had 1.7 billion yuan in total assets and 229.6 million yuan in total liabilities, with a liability-to-asset ratio of 13.7%.

This article was automatically produced by Caixin Automation on Nov. 3, 2021.

Download our app to receive breaking news alerts and read the news on the go.

Follow the Chinese markets in real time with Caixin Global’s new stock database.